Vaccine mix-and-match: U.K. to study efficacy of combining shots

British scientists are starting a study Thursday to find out if it’s OK to mix and match COVID-19 vaccines.

The vaccines being rolled out now require two doses, and people are supposed to get two shots of the same kind, weeks apart.

Guidelines in Britain, Canada and U.S. say the vaccines aren’t interchangeable, but can be mixed if the same kind isn’t available for the second dose or if it’s not known what was given for the first shot.

Participants in the government-funded study will get one shot of the AstraZeneca vaccine followed by a dose from Pfizer, or vice versa.

“This study will give us greater insight into how we can use vaccines to stay on top of this nasty disease,” said Jonathan Van Tam, the U.K.’s deputy chief medical officer.

He said that given the challenges of immunizing millions of people amid a global vaccine shortage, there would be advantages to having data that could support more “flexible” immunization campaigns.

COVID-19 vaccines all train the body to recognize the coronavirus, mostly the spike protein that coats it. The ones from AstraZeneca and Pfizer use different technologies. AstraZeneca’s uses a common cold virus to carry the spike gene into the body. Pfizer’s is made by putting a piece of genetic code called mRNA — the instructions for that spike protein — inside a little ball of fat.

Get breaking National news

For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen.

Sign up for breaking National newsletter Sign Up

By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

The British research is scheduled to run 13 months and will also test different intervals between doses, four weeks and 12 weeks apart.

A study published this week on the Russian-made Sputnik V vaccine showed it was about 91% effective in preventing COVID-19. Some immunologists credit the fact that the vaccine uses two slightly different shots, made with similar technology to AstraZeneca’s.

1:52 Coronavirus: Boris Johnson says U.K. confident in vaccine contracts, supply when asked about Astrozeneca-EU dispute

But the AstraZeneca and Pfizer vaccines are “so different that it’s really hard to know if that would work,” said Alexander Edwards, an associate professor in biomedical technology at Britain’s University of Reading.

Matthew Snape, the new study’s leader at Oxford University, which helped develop the AstraZeneca vaccine, called for British volunteers over age 50 to sign up; scientists are hoping to enrol more than 800 people.

If the vaccines can be used interchangeably, “this will greatly increase the flexibility of vaccine delivery,” he said in a statement. “(It) could provide clues as to how to increase the breadth of protection against new virus strains.”

In recent weeks, Britain, the European Union and numerous other countries have been hit with vaccine supply issues: AstraZeneca said it would dramatically reduce the expected number of doses it could deliver due to manufacturing delays and Pfizer also slowed deliveries while it upgraded its Belgian factory.